Indeed, the patient benefit of treatment with EGFR inhibitors in EGFR-mutated lung adenocarcinoma (LUAD) is well established.7 Unfortunately, attempts to inhibit EGFR signaling in GBM have not yet proven to be beneficial.8,9. This evidence concerns the gene EGFR and lung adenocarcinoma.